ProCE Banner Activity

How I Individualize Therapy for Patients With Chronic Lymphocytic Leukemia

Clinical Thought
Get an expert’s perspective on how recent developments may affect the current standard of care for patients with CLL.

Released: July 25, 2022

Expiration: July 24, 2023

No longer available for credit.

Share

Faculty

William G. Wierda

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

BeiGene

Janssen administered by Scientific Affairs

Pharmacyclics an AbbVie Company

Program Director Disclosure

Program Director

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD: consultantAbbVie, AstraZeneca/Acerta, Cyclacel, Genentech, Gilead Sciences, GlaxoSmithKline/Novartis, Janssen, Juno, Kite, Loxo Oncology/Lilly, Miragen, Oncternal Therapeutics, Pharmacyclics, Sunesis, Xencor.